In:
Hepatology Research, Wiley, Vol. 47, No. 6 ( 2017-05), p. 514-521
Abstract:
To assess the efficacy and safety of telaprevir (TVR) in combination with pegylated interferon α‐2a (PEG‐IFNα‐2a) and ribavirin (RBV) for treatment‐naïve patients and relapsed patients compared to previous TVR‐based triple therapy in Japan. Methods The study group included 35 treatment‐naïve (median age, 55 years) and 19 relapsed (median age, 55 years) patients with genotype 1 hepatitis C virus infection. Patients received TVR (750 mg every 8 h) for 12 weeks, in combination with PEG‐IFNα‐2a and RBV. Results The sustained virological response (SVR 24 ) rates for naïve and relapsed patients were 85.7% (30/35) and 94.7% (18/19), respectively. The discontinuation rate of all study drugs due to adverse events was 5.6% (3/54). Among the 54 patients, grade 3 skin disorders and grade 3 anemia ( 〈 8.0 g/dL) were reported in 2 (3.7%) and 6 patients (11.1%), respectively. Although the overall safety profiles were similar for the TVR/PEG‐IFNα‐2a/RBV and TVR/PEG‐IFNα‐2b/RBV regimens (previous study), the proportion of patients discontinuing all study drugs due to adverse events was lower in the patients treated with the TVR/PEG‐IFNα‐2a/RBV regimen (3/54, 5.6%) than TVR/PEG‐IFNα‐2b/RBV regimen (44/267, 16.5%). Conclusion Telaprevir in combination with PEG‐IFNα‐2a/RBV provided a high sustained virological response rate for the treatment of genotype 1 hepatitis C virus in both treatment‐naïve and relapsed patients in Japan. Telaprevir‐based therapy may provide a useful treatment option for patients who are difficult to treat due to NS5A (Y93, L31) and NS3/4A (D168) variants.
Type of Medium:
Online Resource
ISSN:
1386-6346
,
1872-034X
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
2006439-1
Permalink
